Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change $ Change
grade C $25.30 0.00% 0.0
ACOR closed unchanged on Tuesday, February 21, 2017, on 86 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Feb 17 NR7 Range Contraction 0.00%
Feb 17 Calm After Storm Range Contraction 0.00%
Feb 16 Stochastic Reached Overbought Other 0.00%
Feb 16 Calm After Storm Range Contraction 0.00%
Feb 15 Spinning Top Other -0.39%
Feb 15 Calm After Storm Range Contraction -0.39%
Feb 14 Calm After Storm Range Contraction 6.08%
Feb 13 Stochastic Reached Overbought Other 3.69%
Feb 13 Slingshot Bullish Bullish Swing Setup 3.69%
Feb 13 Calm After Storm Range Contraction 3.69%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.36
52 Week Low 16.4
Average Volume 760,449
200-Day Moving Average 23.1
50-Day Moving Average 21.08
20-Day Moving Average 22.47
10-Day Moving Average 24.06
Average True Range 1.23
ADX 21.52
+DI 32.88
-DI: 16.03
Chandelier Exit (Long, 3 ATRs) 22.46
Chandelier Exit (Short, 3 ATRs) 22.99
Upper Bollinger Band 26.56
Lower Bollinger Band 18.38
Percent B (%b) 0.85
Bandwidth 0.364041